These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6518677)

  • 1. Hypermineralocorticoidism due to topical application of 9 alpha-fluoroprednisolone.
    Sanchez M; Perez-Garcia R; Lazaro P; López-Gomez JM; Valderrábano F
    Clin Nephrol; 1984 Nov; 22(5):267-8. PubMed ID: 6518677
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypopotassemic myopathy caused by topical administration of 9 alpha fluoroprednisolone].
    Molins A; Alvarez-Sabín J; Montalbán J; Molero J; Alegre J; Codina A
    Neurologia; 1987; 2(5):244-6. PubMed ID: 3274232
    [No Abstract]   [Full Text] [Related]  

  • 3. [Arterial hypertension secondary to the application of 9-alpha-fluoroprednisolone ointments].
    Arnal JM; Moneo MI; Loris C
    An Esp Pediatr; 1987 Jan; 26(1):65-6. PubMed ID: 3826948
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudoaldosteronism due to 9-alpha-fluoroprednisolone creams.
    Morán JM; De Sancho JL; Abaigar P; Amenabar J; Muñiz R; Lampreabe I
    Clin Nephrol; 1984 Dec; 22(6):323-4. PubMed ID: 6525775
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypokalemic myopathy and metabolic alkalosis secondary to the topical application of 9-alpha-fluoroprednisolone].
    Pachón Diaz J; López Cortés L; Navarro Rodríguez A; García Criado F
    Rev Clin Esp; 1983 Sep; 170(5):221-2. PubMed ID: 6647945
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypermineralcorticism syndrome secondary to topical application of 9-alpha-fluoroprednisolone (author's transl)].
    Vasconez F; Pérez-Garcia R; Olivas E; Bolívar JE; Valderrábano F
    Med Clin (Barc); 1980 Dec; 75(10):430-4. PubMed ID: 7464329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudohyperaldosteronism due to application of an antihemorrhoid cream.
    Marin F; González Quintela A; Moya M; Suárez E; de Zárraga M
    Nephron; 1989; 52(3):281-2. PubMed ID: 2739869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypokalemic alkalosis due to 9-alpha-fluoroprednisolone locally applied in pemphigus vulgaris].
    Scarpa C; Gentilli G
    G Ital Dermatol Venereol; 1983; 118(3):179-81. PubMed ID: 6546245
    [No Abstract]   [Full Text] [Related]  

  • 9. Pseudoaldosteronism due to 9-alpha-fluoroprednisolone creams.
    Praga M; Maiz E; Mijares RP; Lopez de Novales E
    Clin Nephrol; 1983 Dec; 20(6):321. PubMed ID: 6641033
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypokalemic rhabdomyolysis secondary to pseudohyperaldosteronism due to the use of a lotion containing 9-alpha-fluoroprednisolone.
    Mijares RP
    Nephron; 1986; 43(3):232-3. PubMed ID: 3724933
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pseudohyperaldosteronism secondary to oral brushing of 9-alpha-fluoroprednisolone. Presentation of a clinical case].
    Rosselli A; Calacoci S; Regoli G; Turchi A
    G Clin Med; 1985; 66(9-10):359-62. PubMed ID: 3833560
    [No Abstract]   [Full Text] [Related]  

  • 12. [Normotensive hypermineralocorticism caused by abusive use of a nasal spray containing 9 alpha-fluoroprednisolone].
    Vincenzi V; Fioroni E; Gambini G; Gradoli C; Benvegnù B; Martella MA; Bartolucci L; Valori C
    Minerva Endocrinol; 1984; 9(3):375-7. PubMed ID: 6533469
    [No Abstract]   [Full Text] [Related]  

  • 13. [Exogenous hypermineralocorticism caused by a nasal spray containing 9-alpha fluoroprednisolone].
    Virgolini L; Geatti O; Giunta G
    Minerva Cardioangiol; 1984; 32(7-8):473-5. PubMed ID: 6208510
    [No Abstract]   [Full Text] [Related]  

  • 14. [Again on the subject of arterial hypertension caused by the chronic cutaneous application of mineralocorticoids].
    Bisignani G; Boncompagni F; Plastina F
    Minerva Endocrinol; 1988; 13(1):16. PubMed ID: 3367885
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe hypopotassemia and rhabdomyolysis in a normotensive subject after use of a nasal spray containing 9-alpha-fluoroprednisolone].
    Wu SC; Secchi MB; Mancarella S; Oltrona L; Bettazzi L; Sale M; Ambrosi B
    Recenti Prog Med; 1989 Apr; 80(4):195-6. PubMed ID: 2762657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis, oedema and arterial hypertension: different syndromes related to topical use of 9-alpha-fluoroprednisolone.
    Lauzurica R; Bonal J; Bonet J; Romero R; Teixido J; Serra A; Caralps A
    J Hum Hypertens; 1988 Oct; 2(3):183-6. PubMed ID: 3236321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudoprimary hyperaldosteronism from topical application of 9-alpha-fluorprednisolone on the skin.
    Brognoli M; Doregatti C; Roncali M; Orlandini G
    Clin Nephrol; 1985 Dec; 24(6):315-6. PubMed ID: 4075602
    [No Abstract]   [Full Text] [Related]  

  • 18. [Case of pseudohyperaldosteronism caused by 9-alpha-fluoroprednisolone abuse].
    Napolitano C; Frezza F; Salera P; Gattini G; Balzanelli M
    Clin Ter; 1985 Jul; 114(1):63-6. PubMed ID: 4042580
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hypermineralocorticism secondary to the topical use of corticoids].
    Rama H; Carreras L; Martínez-Amenos A; Sarrias X
    Rev Clin Esp; 1984 Aug 15-31; 174(3-4):111-4. PubMed ID: 6515071
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hypermineralcorticism caused by topical preparation containing 9-alpha-fluoroprednisolone].
    Zamora Martínez E; Martín Moreno L; de Castro Torres A
    Med Cutan Ibero Lat Am; 1988; 16(5):431-2. PubMed ID: 3070202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.